Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool April 23, 2009 Brian Orelli	Elan's Strategic Uncertainty Elan has nothing new to report yet on the strategic review that Citigroup is preparing for them.
The Motley Fool October 28, 2011 Brian Orelli	Focus on Profits, Biotech Investors Elan is in the black and looking as healthy as ever.
The Motley Fool February 9, 2011 Brian Orelli	Once a Decade Isn't Enough, Elan Elan posts its first operating profit in 10 years.
The Motley Fool October 22, 2009 Brian Orelli	Elan's Headed in the Right Direction Revenue up, costs down. It's a good direction for Elan to take, even if the company's final earnings number was slightly inflated.
The Motley Fool February 11, 2010 Brian Orelli	Blockbuster in Hand, It's Time to Show a Profit Elan predicts an operating profit for the first time in nine years.
The Motley Fool September 15, 2009 Brian Orelli	What's $115 Million Between Friends? Elan has to fix the mess it had gotten itself into with its multiple sclerosis drug Tysabri.
The Motley Fool December 19, 2011 Brian Orelli	Elan Turns It Around in 2011 Let's hope next year is as productive.
The Motley Fool October 30, 2008 Brian Orelli	Not What the Doctor Ordered Biogen reports a third case of a deadly brain disorder since their multiple sclerosis drug Tysabri made its return.
The Motley Fool April 21, 2011 Brian Orelli	Tysabri Means Everything to Biogen and Elan ... for Now It's rare to find a drug that affects two companies as much as Tysabri does Biogen Idec and Elan.
The Motley Fool February 22, 2007 Brian Lawler	Too Much Aplomb From Elan Elan releases its 2006 financial results, and its future is not as rosy as seems. Investors, take note.
The Motley Fool September 30, 2009 Brian Orelli	More Questions Than Answers From Elan Things that make you go hmmm.
The Motley Fool March 15, 2007 Anders Bylund	Dueling Fools: Elan Bull Granted, Elan isn't a stock for impatient investors, but those with patience will be rewarded in spades.
The Motley Fool January 2, 2012 Anders Bylund	What Will Elan Do for an Encore? 2011 was a great year for the Irish biotech. Here's how that momentum carries through into 2012.
The Motley Fool April 3, 2009 Brian Orelli	Toning Down a Treatment Elan and Wyeth drop the highest dose of their Alzheimer's drug.
The Motley Fool December 15, 2009 Brian Orelli	Forget the Higher Doses Elan has to drop the highest dose of an Alzheimer's drug. Again.
The Motley Fool December 28, 2010 Brian Orelli	No Guts, No Glory For better or worse, Elan gains full control of Alzheimer's drug ELND005.
The Motley Fool October 22, 2008 Brian Orelli	Biogen Has Growth in all the Wrong Places Biogen Idec saw substantial growth in the third quarter, but apparently it's coming from all the wrong places.
The Motley Fool February 10, 2009 Brian Orelli	Elan Needs a Face-Lift Elan is in need of a serious makeover. The company has been beaten down severely, but there's still plenty of beauty in this pharma.
The Motley Fool March 31, 2005 Stephen D. Simpson	Strike Three for Tysabri A third confirmed case of PML all but eliminates Tysabri's potential as a blockbuster drug. For Elan and Biogen investors, the news continues to sting.
The Motley Fool February 18, 2004 Jeff Hwang	Elan's Early Submission Elan and Biogen Idec will submit a multiple sclerosis treatment ahead of schedule.
The Motley Fool June 1, 2009 Brian Orelli	Going Up for All the Wrong Reasons Bristol-Myers has been identified as Elan's mystery bidder. So what?
The Motley Fool October 31, 2006 Brian Lawler	A Foolish Trick: Elan Debt is coming due, and there's too much reliance on a single drug. Investors, beware.
Chemistry World February 8, 2013 Andrew Turley	Biogen buys Tysabri from Elan for $3.25bn US biotech Biogen Idec is to pay $3.25 billion to Irish drugmaker Elan for full rights to Tysabri (natalizumab) injections for the treatment of multiple sclerosis.
The Motley Fool February 28, 2005 Charly Travers	Another Drug Sector Shocker Patient death triggers voluntary withdrawal of MS drug Tysabri. Both BiogenIDEC and Elan have been rocked in trading today, down 41% and 68%, respectively, so far.
The Motley Fool May 22, 2007 Brian Lawler	Elan Plunges Ahead Shares of the drugmaker Elan have climbed more than 20% in the past two days after the company announced that it and partner Wyeth were moving their lead Alzheimer's disease treatment into phase 3 testing.
The Motley Fool June 29, 2009 Brian Orelli	Another Day, Another Rumored Suitor The rumors surrounding Elan's strategic review and its suitors just keep getting weirder.
The Motley Fool April 25, 2007 Brian Lawler	Where Is Elan Going? Drugmaker Elan announces first-quarter financial results. Investors, take note.
The Motley Fool September 4, 2009 Brian Orelli	The Billion-Dollar Lovers' Quarrel Continues Elan had better bring candy and flowers to patch this up.
The Motley Fool June 30, 2009 Brian Orelli	Here We Go Again With Tysabri The number of patients on Biogen Idec's and Elan's multiple sclerosis drug, Tysabri, that have gotten progressive multifocal leukoencephalopathy since the drug was reintroduced to the market has reached double digits.
The Motley Fool March 8, 2005 Charly Travers	After the Crash, Is Biogen IDEC a Buy? Biogen stock plunge may be an overreaction to pulling multiple sclerosis drug Tysabri off the market.
The Motley Fool June 18, 2007 Billy Fisher	Elan Elevates Its Game New drug prospects push the Dublin-based biotech's shares to a new 52-week high.
The Motley Fool August 1, 2008 Brian Lawler	Elan Becomes a Bad News Buy Shares of Elan are now undervalued, thanks to a big price drop following bad new about their multiple sclerosis drug.
The Motley Fool February 27, 2009 Brian Orelli	Elan's Crash Diet Looks Good Elan needed a makeover, and the new, thinner company is looking better already.
The Motley Fool July 2, 2009 Brian Orelli	Squeezing Blood From a Half-Dollar Johnson & Johnson is investing $1 billion in Elan in exchange for an 18.4% stake in the company.
The Motley Fool October 1, 2009 Anders Bylund	Why I'm Invested in Tysabri and Elan This Motley Fool analyst has investigated Elan both as an investor and a patient. What's his verdict on the company?
The Motley Fool July 17, 2009 Brian Orelli	Tysabri Is Back! News about Biogen Idec and Elan's multiple sclerosis drug revenues, as well as those of Pfizer and Teva.
The Motley Fool October 25, 2007 Brian Lawler	Tysabri, Elan, and a Prayer Investors seem impressed with Irish drugmaker Elan's third-quarter results; sales of their multiple sclerosis drug are picking up, but can they grow into the stock's valuation?
The Motley Fool August 7, 2009 Brian Orelli	A Billion-Dollar Lovers' Quarrel It looks like the triangle between partners Elan and Biogen Idec and third-wheel Johnson & Johnson over the multiple sclerosis drug Tysabri is going to get settled in court.
The Motley Fool February 22, 2011 Brian Orelli	Biogen and Elan's Growing Problem More cases of potentially lethal PML.
The Motley Fool January 21, 2011 Brian Orelli	Trouble in Tysabri Land? Patient additions for a drug from Biogen Idec and Elan are slowing down.
The Motley Fool February 2, 2011 Brian Orelli	A Deeper Dive Into Biogen's Revenue Growth On the surface, it looks like Biogen Idec is handling the entrance of Novartis' new oral multiple sclerosis drug, Gilenya, quite well. The real picture is a little bleaker.
The Motley Fool August 10, 2010 Brian Orelli	Elan's Alternative to Strategic Alternatives Sometimes doing nothing is the best option.
Chemistry World February 27, 2013 Andrew Turley	Talk of a $6.6bn deal for Elan Irish drug maker Elan has been surprised by a potential $6.6 billion offer being mooted by investment firm Royalty Pharma.
The Motley Fool August 26, 2008 Brian Lawler	FDA Changes Course for Elan and Biogen Idec The agency takes a different tack with one of the partnership's top drugs.
The Motley Fool May 26, 2004 Charly Travers	Elan and Biogen File for Approval There's a new multiple sclerosis drug on the horizon.
The Motley Fool January 25, 2010 Brian Orelli	Tysabri Updates: All You Have to Do Is Ask Biogen Idec is willing to hook medical doctors up with an automatic monthly update of the number of progressive multifocal leukoencephalopathy cases for people taking it and Elan's multiple sclerosis drug, Tysabri.
The Motley Fool March 15, 2007 Brian Lawler	Dueling Fools: Elan Bear How do you bring an Elan bear out of hibernation? Combine a crushing debt load, a huge cloud of uncertainty over its lead developmental drug program, and the launch of a new product that won't bring in enough revenue to sustain the current valuation, et voila! A bear is born.
The Motley Fool July 30, 2007 Brian Lawler	The Good and Bad of Elan Investors, any bet on Elan is primarily a bet on the outcomes of Tysabri and AAB-001.
The Motley Fool April 5, 2005 Charly Travers	Has Elan Been KO'd? Tysabri is derailed but not necessarily off-track forever. The FDA needs to consider whether the real benefits to these patients outweigh the risk. But that's a highly uncertain outcome and a heck of decision on which to bet some investment dollars.
The Motley Fool October 20, 2009 Brian Orelli	All Tysabri, All the Time Biogen needs to focus on its most potential-packed drug.